Pharmaceutical products

Tender description

Invitation to offer for NHS Pharmaceuticals 2017_2. Offer reference number: CM/PHG/15/5491. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months. Potential periods of call-offs under the framework agreement: CESW: 1.8.2018 to 28.2.2019 (7 months), NWLN: 1.8.2018 to 31.7.2019 (12 months), LSNE: 1.8.2018 to 31.1.2020 (18 months). Products on the framework include (but are not necessarily limited to): Abacavir, Abiraterone, Anidulafungin, Atovaquone, Bosentan, Ciclesonide, Drospirenone / Ethinylestradiol, Enfurvitide, Ethinylestradiol / Norelgestromin, Exenatide, Ezetimibe, Iloprost, Ivabradine, Mycophenolic acid, Nitisinone, Olopatadine, Oseltamivir, Parecoxib, Pegfilgrastim, Pegvisomant, Pregabalin, Tadalafil, Tenofovir, Tigecycline, Valproic acid, Velaglucerase. Details of presentation sizes and volumes are within the tender document set. NHS Pharmaceutical Products 2017_2. Offer reference number: CM/PHG/15/5491. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months. Potential periods of call-offs under the framework agreement: CESW: 1.8.2018 to 28.2.2019 (7 months), NWLN: 1.8.2018 to 31.7.2019 (12 months), LSNE: 1.8.2018 to 31.1.2020 (18 months). NHS Pharmaceuticals 2017_2. Offer reference number: CM/PHG/15/5491. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months. Potential periods of call-offs under the framework agreement: CESW: 1.8.2018 to 28.2.2019 (7 months), NWLN: 1.8.2018 to 31.7.2019 (12 months), LSNE: 1.8.2018 to 31.1.2020 (18 months). Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.